Gyre Therapeutics shows a highly favorable modeled asymmetry and a recovering technical setup, but value-trap signals from margin compression, a confirmed prior downtrend, material insider selling, and the absence of a clear trading edge together support the recommendation to consider reducing the position.
Thesis pillars
- Value Trap Margin Compression↑Improving
- Confirmed Technical Downtrend↑Improving
- High Asymmetry Speculative Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 13, 2026
Gyre Therapeutics, Inc. (GYRE) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.09: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 8.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, commercializing products in China through its majority-owned subsidiary Gyre Pharmaceuticals while running US clinical trials from... Read more
Sell if holding. Engine safety override at $7.09: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 8.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Trend continuation, RSI 56, MACD bullish. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: speculative.
About Gyre Therapeutics, Inc.
About Gyre Therapeutics, Inc.
Gyre Therapeutics sells three approved fibrosis and liver-disease therapies in China, ETUARY (pirfenidone), Etorel (nintedanib) and Contiva (avatrombopag), which together generated $116.2 million in 2025 revenue, with ETUARY alone accounting for $106.1 million. The company's lead pipeline asset, Hydronidone, met its primary endpoint in a PRC Phase 3 trial for chronic hepatitis B-associated liver fibrosis and is advancing through Phase 1 testing in the United States for MASH.
Gyre Pharmaceuticals earns revenue by selling ETUARY, Etorel and Contiva to PRC hospitals and pharmacies, competing for placement through the government's centralized tender process and depending on continued inclusion on China's National Reimbursement Drug List for reimbursement support. ETUARY has held a leading position in the pulmonary fibrosis market since its 2017 NRDL listing, though its share has eroded as rival therapies such as OFEV (nintedanib), which generated $76.9 million in PRC sales in 2024, gain ground. Beyond the marketed portfolio, Gyre is funding a broader liver- and lung-disease pipeline, including F573 for acute liver failure (Phase 2), F230 for pulmonary arterial hypertension (Phase 1) and F528 for COPD (preclinical), alongside Hydronidone's parallel PRC and US development tracks. On March 2, 2026, the company agreed to acquire Cullgen Inc. in an all-stock deal valuing the target at approximately $300 million, a transaction it completed on May 4, 2026.
Show full overview
Gyre's revenue base carries acute single-product dependency: the 10-K states its business is significantly dependent on sales of ETUARY amid rising competition from rivals like OFEV, and the company acknowledges it may be unable to diversify away from that reliance despite launching Etorel and Contiva in 2025. The nearest catalyst that could change this is Hydronidone, which met its Phase 3 primary endpoint in China in May 2025, with 52.85% of treated patients achieving fibrosis regression versus 29.84% on placebo, and is targeted for an NDA submission seeking conditional approval in the first half of 2026.
See also: Healthcare · Biotechnology
From Gyre Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Gyre Therapeutics, Inc.
Latest news
- NEWS Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat — MarketBeat neutral
- NEWS GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 39.84% as Shares Slip 1.03% - dars.gov.et — dars.gov.et positive
- NEWS Gyre Therapeutics (GYRE) to Post Quarterly Earnings on Monday - MarketBeat — MarketBeat neutral
- NEWS GYRE|Gyre Therapeutics Inc|Price:5.750|Chg%:-0.060 - TradingKey — TradingKey neutral
- NEWS Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
Generated 2026-10-29T11:14:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- MEDIUMProductETUARY® (pirfenidone)10-K Item 1A: 'Our business is significantly dependent on the sales of ETUARY®, one of our marketed products in the PRC'
Material Events(8-K, last 90d)
- 2026-05-04Item 2.01MEDIUMGyre Therapeutics completed its previously announced all-stock acquisition of Cullgen Inc., valuing Cullgen at approximately $300 million; Cullgen became a wholly owned subsidiary.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -19.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.09: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 8.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: Trend continuation, RSI 56, MACD bullish. Prior stop was $6.59. Score 5.6/10, moderate confidence.
Analyst target: $15.87 (+123.8% upside). Prior stop was $6.59. Stop-loss: $6.59.
Quality below floor (3.6 < 4.0).
Gyre Therapeutics, Inc. trades at a P/E of N/A (forward 118.2). TrendMatrix value score: 5.7/10. Verdict: Sell.
9 analysts cover GYRE with a consensus score of 4.2/5. Average price target: $19.
What does Gyre Therapeutics, Inc. do?Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ...
Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, commercializing products in China through its majority-owned subsidiary Gyre Pharmaceuticals while running US clinical trials from San Diego. Its three marketed drugs, ETUARY®, Etorel® and Contiva®, generated combined sales of $116.2 million in 2025, with ETUARY® alone contributing $106.1 million. The pipeline is led by Hydronidone, in Phase 3 for liver fibrosis in China and Phase 1 for MASH-associated liver fibrosis in the US.